Pfizer and Astellas have unveiled results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Xtandi significantly improved radiographic progression-free survival, paving the way for an application to expand the drug's use.Original Article
You may also like
Exploring 3D Printing for Solid Dosage Drugs
Control Strategies and Method Development for...
CPHI Milan 2024: Fill/Finish and Sustainability
CPHI Milan 2024: Industry Trends Impacting Oral Solid...
CPHI Milan 2024: Evolution of Coating Design
Colorcon and LOTTE Fine Chemical Announce Partnership
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.